Eli Lilly Japan Receives Additional Approval for Vancomycin Hydrochloride for Injection

Eli Lilly Japan Receives Additional Approval for Vancomycin Hydrochloride for Injection

Tokyo (JCNN) - Eli Lilly Japan has announced that it has received additional approval for Vancomycin Hydrochloride Injection 0.5g, its injectable glycopeptide antibiotic for Gram-positive infections.

Vancomycin Hydrochloride Infection can now be used for treatment of penicillin-resistant streptococcus pneumoniae (PRSP) infections.

Manufactured at Seishin Laboratories of Eli Lilly Japan, the product is currently distributed through Shionogi.

Copyright(C) 2004 Japan Corporate News Network. www.japancorp.net All rights reserved.

Home Marketing Services News Reports Company Profiles InDepth Drug Discovery Careers Conferences Videos Search Contact
	Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner. See User Agreement Send comments and feedback to: Peter Barfoot Managing Director, BioPortfolio Ltd. UK Tel: (+44) 1300 321501 USA Voicemail and Fax: (+1) 415 680 2472	All rights reserved. All other trademarks recognized. BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10 Copyright © 1997-2008 - BioPortfolio Limited.